SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 12/11/2025 at 07:00, 1 month 20 days ago

Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
Sanofi's Qfitlia and Cablivi have been approved in China by the National Medical Products Administration, expanding care for rare diseases in the country. Qfitlia offers protection for hemophilia with as few as six injections a year, while Cablivi targets a rare life-threatening blood clotting disorder

China Sanofi Rare Diseases Qfitlia Cablivi
PRESS RELEASE

published on 12/11/2025 at 07:00, 1 month 20 days ago

Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares
Sanofi voit Qfitlia et Cablivi approuvés en Chine pour traiter les maladies rares, marquant une avancée significative avec des approbations récentes dans le domaine de l'hématologie

Chine Sanofi Maladies Rares Qfitlia Cablivi
BRIEF

published on 12/04/2025 at 11:05, 1 month 27 days ago

Sanofi Completes Acquisition of Vicebio

Respiratory Viruses Sanofi Acquisition Molecular Clamp Vicebio Vaccine Vaccine Pipeline
BRIEF

published on 12/04/2025 at 11:05, 1 month 27 days ago

Sanofi finalise l'acquisition de Vicebio

Acquisition De Sanofi Virus Respiratoires Vaccin Vicebio Pince Moléculaire Pipeline Des Vaccins
PRESS RELEASE

published on 12/04/2025 at 11:00, 1 month 27 days ago

Communiqué de presse : Sanofi finalise l’acquisition de Vicebio
Sanofi finalise l’acquisition de Vicebio et renforce son pipeline de vaccins respiratoires avec un candidat-vaccin innovant contre le virus respiratoire syncytial (VRS) et le métapneumovirus humain (HMPV)

Acquisition Sanofi Vaccin Vicebio Respiratoire
PRESS RELEASE

published on 12/04/2025 at 11:00, 1 month 27 days ago

Press Release: Sanofi completes acquisition of Vicebio
Sanofi completes acquisition of Vicebio, enhancing its vaccine portfolio with a combination vaccine candidate for RSV and HMPV. The 'Molecular Clamp' technology expands vaccine design capabilities

Acquisition Sanofi Vaccine Candidate RSV Vicebio
BRIEF

published on 11/25/2025 at 07:05, 2 months 6 days ago

Dupixent : une avancée dans le traitement de l'urticaire chronique spontanée en Europe

Sanofi Dupixent Regeneron Traitement Innovant Urticaire Chronique
BRIEF

published on 11/25/2025 at 07:05, 2 months 6 days ago

Dupixent: a breakthrough in the treatment of chronic spontaneous urticaria in Europe

Innovative Treatment Sanofi Dupixent Regeneron Chronic Urticaria
PRESS RELEASE

published on 11/25/2025 at 07:00, 2 months 6 days ago

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée
Dupixent de Sanofi et Regeneron approuvé dans l'UE pour l'urticaire chronique spontanée. Impact positif sur les patients avec symptômes malgré antihistaminiques. Nouvelle option thérapeutique basée sur inhibition IL4 et IL13

Traitement Sanofi Dupixent Regeneron Urticaire
PRESS RELEASE

published on 11/25/2025 at 07:00, 2 months 6 days ago

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron receive EU approval for Dupixent as targeted medicine for chronic spontaneous urticaria, significantly reducing itch and hives compared to placebo

Sanofi Dupixent EU Approval Regeneron Chronic Spontaneous Urticaria

Published on 01/31/2026 at 03:15, 19 hours 4 minutes ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 19 hours 59 minutes ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 20 hours 39 minutes ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 22 hours 19 minutes ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 23 hours 19 minutes ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 15:54, 6 hours 25 minutes ago

EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 9 hours 54 minutes ago

JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 19 hours 34 minutes ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 1 day 2 hours ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026

View all EQS

Published on 01/30/2026 at 18:40, 1 day 3 hours ago

ICADE - Bilan semestriel du contrat de liquidite
Published on 01/30/2026 at 18:01, 1 day 4 hours ago

Emova Group - Résultats annuels 2024/25
Published on 01/30/2026 at 17:45, 1 day 4 hours ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 17:45, 1 day 4 hours ago

Schneider Electric lance une augmentation de capital réservée aux salariés
Published on 01/30/2026 at 08:30, 1 day 13 hours ago

Claude Bernard lance Senior+, un assistant IA conçu pour améliorer la prise en charge des patients les plus âgés

View all LES ECHOS COMFI WIRE

News